Halozyme Therapeutics Inc (NASDAQ: HALO) is 20.14% higher on its value in year-to-date trading and has touched a low of $35.50 and a high of $65.53 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The HALO stock was last observed hovering at around $57.77 in the last trading session, with the day’s loss setting it -0.33%.
Currently trading at $57.44, the stock is 0.71% and 8.68% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.54 million and changing -0.57% at the moment leaves the stock 8.37% off its SMA200. HALO registered 59.11% gain for a year compared to 6-month loss of -6.96%.
The stock witnessed a 2.68% gain in the last 1 month and extending the period to 3 months gives it a 25.83%, and is -1.15% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.17% over the week and 2.44% over the month.
Halozyme Therapeutics Inc (HALO) has around 350 employees, a market worth around $7.07B and $1.02B in sales. Current P/E ratio is 16.73 and Fwd P/E is 8.54. Profit margin for the company is 43.74%. Distance from 52-week low is 61.80% and -12.35% from its 52-week high. The company has generated returns on investments over the last 12 months (23.46%).
with sales reaching $229.29M over the same period.The EPS is expected to grow by 19.62% this year, but quarterly earnings will post 16.86% year-over-year. Quarterly sales are estimated to grow 17.06% in year-over-year returns.
The shares outstanding are 123.14M, and float is at 121.82M with Short Float at 7.43%.
The top institutional shareholder in the company is BLACKROCK INC. with over 17.62 million shares valued at $922.58 million. The investor’s holdings represent 13.8804 of the HALO Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 12.88 million shares valued at $674.47 million to account for 10.1476 of the shares outstanding. The other top investors are STATE STREET CORP which holds 5.81 million shares representing 4.5802 and valued at over $304.43 million, while SNYDER CAPITAL MANAGEMENT L P holds 3.1781 of the shares totaling 4.04 million with a market value of $211.53 million.
Halozyme Therapeutics Inc (HALO) Insider Activity
The most recent transaction is an insider sale by Henderson Jeffrey William, the company’s Director. SEC filings show that Henderson Jeffrey William sold 5,000 shares of the company’s common stock on Feb 03 ’25 at a price of $56.30 per share for a total of $0.28 million. Following the sale, the insider now owns 38611.0 shares.
Still, SEC filings show that on Jan 06 ’25, Henderson Jeffrey William (Director) disposed off 10,000 shares at an average price of $50.01 for $0.5 million. The insider now directly holds 43,611 shares of Halozyme Therapeutics Inc (HALO).
